Watch ORGO. Know when insiders buy.
One email the day a filing lands. Free.
ORGO
Organogenesis Holdings Inc.
1.42
−0.03 −2.07%
USD · close Sep 24
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
50
WATCH · shorts 50
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $182.7MP/E —DIV YIELD —FCF YIELD 11.41%REV TTM $457.5M +6.5%NET INCOME −$84.2MNET DEBT $16.2M52W 1.36 – 6.54SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $43.8M | −56.7% | — | −$51M | −$96.3M | — | -0.77 | −$31.7M | $1.1M | −$32.8M | Aug 6 |
| Q1 2026 · Mar 31 | $37.2M | −57.1% | — | −$68.9M | −$53.2M | — | -0.44 | $21.1M | $3.1M | $18M | May 7 |
| Q4 2025 · Dec 31derived | $225.6M | +78.1% | — | $63.3M | $43.7M | +469.5% | 0.27 | $39.4M | $4.7M | $34.8M | Feb 26 |
| Q3 2025 · Sep 30 | $150.9M | +31.0% | — | $20.7M | $21.6M | +74.9% | 0.11 | $3.1M | $2.2M | $844K | Nov 6 |
| Q2 2025 · Jun 30 | $101M | −22.4% | — | −$12.6M | −$9.4M | — | -0.10 | −$32.9M | $3.6M | −$36.5M | Aug 6 |
| Q1 2025 · Mar 31 | $86.7M | −21.2% | 72.6% | −$26.7M | −$18.8M | — | -0.17 | −$19.9M | $3.6M | −$23.6M | May 7 |
| Q4 2024 · Dec 31derived | $126.7M | +27.1% | 75.5% | $10.2M | $7.7M | — | 0.04 | $10.9M | $3.4M | $7.6M | Feb 26 |
| Q3 2024 · Sep 30 | $115.2M | +6.1% | 76.7% | $6.2M | $12.3M | +289.4% | 0.09 | $8.7M | $2.6M | $6.1M | Nov 6 |
| Q2 2024 · Jun 30 | $130.2M | — | 77.6% | −$13.9M | −$17M | — | -0.13 | $4.7M | $1.9M | $2.9M | Aug 7 |
| Q1 2024 · Mar 31 | $110M | — | 73.9% | −$3.9M | −$2.1M | — | -0.02 | −$10.2M | $2.2M | −$12.4M | May 8 |
| Q4 2023 · Dec 31derived | $99.7M | — | 72.1% | −$1.3M | −$568K | — | 0.00 | $10.6M | $3.3M | $7.3M | Feb 26 |
| Q3 2023 · Sep 30 | $108.5M | — | 76.2% | $8.1M | $3.2M | — | 0.02 | $16.7M | $6M | $10.8M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $564.2M | — | $44.7M | $37M | 6.6% | 0.15 | −$10.3M | $14.2M | −$24.5M | — | — |
| FY2024 · to Dec 31 | $482M | 76.0% | −$1.3M | $861K | 0.2% | -0.01 | $14.2M | $10M | $4.2M | $25.5M | — |
| FY2023 · to Dec 31 | $433.1M | 75.4% | $12.5M | $4.9M | 1.1% | 0.04 | $30.9M | $24.4M | $6.6M | $0 | — |
| FY2022 · to Dec 31 | $450.9M | 76.7% | $22.3M | $15.5M | 3.4% | 0.12 | $24.9M | $33.9M | −$9M | $0 | — |
| FY2021 · to Dec 31 | $467.4M | 75.6% | $72.2M | $94.2M | 20.2% | 0.70 | $62M | $31.2M | $30.8M | — | — |
| FY2020 · to Dec 31 | $338.3M | 74.2% | $26.7M | $17.2M | 5.1% | 0.15 | $5.5M | $17.7M | −$12.2M | — | — |
Every number comes from Organogenesis Holdings Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.